Evidence-aware
Safety focused
Women’s Health Clinic FAQ
What is NewGyn?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The key decision is whether the symptom has been properly assessed first.
Direct answer
NewGyn is an intimate-area biorevitalisation product that combines polynucleotides with non-crosslinked hyaluronic acid and mannitol. It is used by some clinics as a non-hormonal injectable option for vulvovaginal dryness, tissue quality and discomfort linked with GSM or vulvovaginal atrophy. It should be presented as an assessment-led treatment option, not a cure or automatic substitute for moisturisers, local hormonal treatment, pelvic-floor care or specialist review.
The safest plan starts by clarifying the symptom, checking red flags, explaining alternatives and agreeing realistic expectations before any procedure is booked.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Key point 1
Contains highly purified Polynucleotides (derived from salmon or trout sperm cells) and 10 mg/ml non-crosslinked Hyaluronic Acid, plus Mannitol.
Purpose
Deep hydration, tissue regeneration, and relief from vaginal dryness, itching, and irritation.
Nature of Treatment
Non-surgical, minimally invasive, and completely hormone-free.
Manufacturer
Mastelli, an Italian company with over 70 years of experience in polynucleotide research and development.
Important safety note
Common Side Effects: Minor and transient side effects include localised redness, swelling, small marks, bruising, and mild tenderness at the injection sites, which typically resolve within a day or two.
Allergy
Technique
Timeline
Aftercare
Detailed answer
How polynucleotides fit into intimate care
Polynucleotides are best explained as biostimulatory DNA fragments rather than fillers. The clinical question is whether they match the diagnosis, tissue findings and safety profile.
Not a standard filler
The aim is gradual tissue-quality support through repair signalling, hydration and extracellular-matrix activity, not instant volume or a promised sexual-function outcome.
Evidence
Symptoms
Alternatives
What it means
Mechanism of Action: Polynucleotides (PN-HPT®) stimulate fibroblast metabolic activity, accelerating cell turnover and enhancing the synthesis of collagen and elastin.
Why it happens
Hydration: Non-crosslinked hyaluronic acid provides immediate deep tissue hydration, while mannitol acts as a water-binding agent and antioxidant to protect the hyaluronic acid from rapid enzymatic degradation.
Evidence limits
Hormone-Free Alternative: It is highly suitable for patients who cannot use or prefer to avoid Hormone Replacement Therapy (HRT), including breast cancer survivors.
Treatment fit
Setting: Administered as an outpatient procedure by trained healthcare professionals.
What this means in practice
Setting: Administered as an outpatient procedure by trained healthcare professionals.
Procedure Duration: The actual injection process takes approximately 10 to 20 minutes.
Patient safety
Why diagnosis comes first
Dryness, soreness, tearing or painful sex may reflect GSM, infection, dermatoses, pelvic-floor guarding or medication effects, so the treatment choice depends on assessment.
It checks the cause
Mechanism of Action: Polynucleotides (PN-HPT®) stimulate fibroblast metabolic activity, accelerating cell turnover and enhancing the synthesis of collagen and elastin.
It protects safety
Common Side Effects: Minor and transient side effects include localised redness, swelling, small marks, bruising, and mild tenderness at the injection sites, which typically.
It reviews alternatives
Setting: Administered as an outpatient procedure by trained healthcare professionals.
It sets expectations
Procedure Duration: The actual injection process takes approximately 10 to 20 minutes.
Non-hormonal does not mean automatic
A hormone-free treatment may still be unsuitable if there is active infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
The consultation should cover product source, allergy risk, alternatives such as moisturisers or local hormonal care, and realistic timelines for tissue response.
Considerations
What to consider
Setting: Administered as an outpatient procedure by trained healthcare professionals.
Consultation priorities
Initial Consultation: The practitioner assesses the patient's symptoms, medical history, and suitability, ensuring no active infections or contraindications are present.
Consent
Aftercare
Follow-up
Before treatment
Initial Consultation: The practitioner assesses the patient's symptoms, medical history, and suitability, ensuring no active infections or contraindications are present.
During care
Treatment Day: After cleansing the area and allowing the topical anaesthetic to take effect, small injections are precisely placed over the targeted areas of the vulva and vagina.
Aftercare
Immediate Aftercare: Patients are advised to refrain from sexual intercourse for 48 to 72 hours.
When to reassess
They should also avoid intense physical activity, hot baths, saunas, steam rooms, and the use of tampons for a few days.
Practical expectations
Procedure Duration: The actual injection process takes approximately 10 to 20 minutes.
Any preparation requirements should be confirmed privately in consultation rather than assumed.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments, usually used for gradual tissue-quality support rather than volume.
Myth: hormone-free means suitable for everyone
Reality: allergy, infection, bleeding, pregnancy, recent surgery and unexplained pain can still make treatment unsuitable.
Myth: hydration means instant repair
Reality: hydration may be noticed earlier, but collagen and tissue-quality changes are gradual and variable.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable clinical result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be more appropriate for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Do not claim intimate polynucleotides cure dryness, laxity, sexual dysfunction, pelvic symptoms, scarring or menopause-related tissue change. Explain that PN products are often fish/marine-derived and allergy history matters.
Are alternatives clear?
Ask what alternatives, aftercare and follow-up plan apply before committing to a course.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, severe fish allergy, pregnancy, recent pelvic surgery or severe pain that has not been assessed.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips or tongue, breathing difficulty, widespread hives, faintness or collapse after exposure needs urgent medical help.
Bleeding or infection
New post-menopausal bleeding, unusual discharge, fever, pelvic pain, thrush, BV or UTI symptoms should be assessed before injectable treatment.
Infection signs
Fever, spreading redness, pus or feeling unwell after a procedure needs urgent advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support cautious, assessment-led patient information and help separate clinical evidence from promotional claims.
PubMed: PN/HA intradermal injections for vulvovaginal atrophy
This pilot study is directly relevant to polynucleotide and hyaluronic acid use in vulvovaginal atrophy.
Real-world study of polynucleotide-based vaginal ovules
This source supports cautious discussion of PN-based vaginal ovules, hydration and atrophy-related symptoms.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 38 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
